Athira Pharma’s experimental Alzheimer’s therapy, fosgonimeton, continues to show reductions in known biomarkers associated with the disease and signs of cognitive and functional improvement in patients with mild-to-moderate Alzheimer’s. On Thursday, Bothell, Wash.-based Athira presented biomarker data from the Phase II ACT-AD study showing that fosgonimeton produced reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) compared […]

Pain relief without toxicity or addiction could become a reality, and South Rampart Pharma’s father-son, surgeons-turned-entrepreneurs duo could hold the key. Dr. Hernan Bazan, CEO and co-founder of the clinical stage pain company, believes it’s on the right track to capitalize not only on a market that is predicted to be valued at $90 billion by 2026, […]

The concept of RNA as a medicine is not new. The act of using ribonucleic acid molecules to treat or prevent diseases by affecting biological pathways has been pursued for almost 50 years. Antisense oligonucleotides were first synthesized in the 1970s; aptamers first described in the 1990s; the first use of exogenous mRNA to induce […]